The Challenge
A global biopharma company was preparing a Global Value Dossier (GVD) for a novel oncology therapy. The Phase III data were strong, but internal teams had concerns:

• No head-to-head trials existed against the most relevant comparator
   

• Evidence was scattered across multiple publications, making messaging inconsistent
   

• Key data gaps (long-term survival, HRQoL) were unaddressed
   

• Early payer simulations predicted tough pushback on comparative effectiveness and budget impact
   

Without a cohesive evidence base, the value proposition risked being challenged by HTA agencies — leading to delays or restricted access.

 

Our Approach: Comprehensive Evidence Synthesis

​

We applied a structured, PRISMA-compliant evidence synthesis strategy designed to support both HTA submissions and the economic model:

​

🔹 Systematic Literature Review (SLR)

• Conducted exhaustive searches across Medline, Embase, Cochrane, and grey literature
   

• Screened and selected studies per pre-specified PICO criteria
   

• Produced evidence tables for efficacy, safety, and HRQoL endpoints
   

🔹 Indirect Treatment Comparison (ITC) & Network Meta-Analysis (NMA)

• Built a robust NMA model to estimate relative efficacy versus the gold-standard comparator
   

• Conducted sensitivity analyses to test assumptions and improve credibility
   

🔹 Evidence Gap Analysis

• Flagged missing long-term outcomes and PRO data
   

• Recommended post-launch RWE collection and inclusion of a patient registry in PMCF plans
   

🔹 Integration into GVD & Value Proposition

• Linked evidence synthesis findings directly to value messages
   

• Included clear visuals showing comparative performance and uncertainty ranges
   

 

The Results

✔️ Strengthened Value Proposition: The narrative was now data-backed, consistent, and payer-relevant

✔️ Defensible Economic Model: Budget impact and cost-effectiveness results were supported by robust, transparent inputs

✔️ Positive HTA Feedback: NICE and CADTH reviewers accepted the NMA methodology without major queries

✔️ Accelerated Market Access: Time-to-decision was reduced by several months compared to internal forecasts

 

The Insight
Evidence synthesis isn’t just a technical deliverable — it’s the engine that powers your value proposition.

​

👉 Lesson Learned: When done systematically and transparently, evidence synthesis builds credibility, closes evidence gaps, and makes payer conversations less about “proving” and more about “aligning.”